LSTM and TB Alliance collaborate to develop new TB therapies
(Liverpool School of Tropical Medicine) This new partnership is supported by the Medical Research Council (MRC) to research drug regimens to fight drug-resistant tuberculosisLSTM and TB Alliance are collaborating to investigate novel combination drug therapies that could help the fight against multidrug-resistant tuberculosis (MDR-TB), following an award of £ 1 million from the Medical Research Council (MRC). (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 19, 2018 Category: Infectious Diseases Source Type: news
The dangers of drug-resistant tuberculosis: What you need to know
There were an estimated 490,000 new cases of multidrug-resistant TB in 2016. (Source: ABC News: Health)
Source: ABC News: Health - September 8, 2018 Category: Consumer Health News Tags: Health Source Type: news
Complete makeover in fight of multidrug-resistant tuberculosis
(McGill University Health Centre) Several new medicines have been found to be more effective than traditional ones used to treat multidrug-resistant tuberculosis (MDR-TB), according to a new international collaborative study led by the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal, with these findings precipitating a complete overhaul of worldwide TB treatment guidelines. The study, led by Dr. Dick Menzies, is published in the British medical journal The Lancet today. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 6, 2018 Category: Infectious Diseases Source Type: news
Relapse-Free Cure From MDR-TB Higher Than Anticipated
TUESDAY, Sept. 4, 2018 -- The frequency of relapse-free cure from multidrug-resistant tuberculosis (MDR-TB) is higher than previously anticipated, according to a study published in the Aug. 1 issue of the American Journal of Respiratory and Critical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 4, 2018 Category: Pharmaceuticals Source Type: news
Tetraphase Pharmaceuticals Announces FDA Approval of Xerava (eravacycline) for Complicated Intra-Abdominal Infections (cIAI)
WATERTOWN, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 27, 2018 Category: Drugs & Pharmacology Source Type: news
SimpliciTB clinical trial launched with first patients in Tbilisi, Georgia
(Burness) TB Alliance has initiated a pivotal clinical trial, SimpliciTB (pronounced: sim-plis-i-tee-bee), that will evaluate whether a new four-drug regimen can treat most types of tuberculosis (TB) including multidrug-resistant TB (MDR-TB) more quickly and effectively than currently-available treatments. The first patients have been enrolled at the National Center for Tuberculosis and Lung Disease in Tbilisi, Georgia. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 27, 2018 Category: Infectious Diseases Source Type: news
Ibalizumab Reduces Viral Load in Multidrug-Resistant HIV-1 Ibalizumab Reduces Viral Load in Multidrug-Resistant HIV-1
Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 25, 2018 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
Study shows children with multidrug-resistant tuberculosis can be treated
(Stellenbosch University) The results of a large, international systematic review published in the journal PLOS Medicine show that tuberculosis treatment is successful in children with multidrug-resistant tuberculosis (MDR-TB). The study was used to inform the World Health Organization guidelines on treatment of MDR-TB in children. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 21, 2018 Category: Infectious Diseases Source Type: news
World Health Organization recommends the use of bedaquiline in all conventional multidrug-resistant tuberculosis treatment regimens
(Source: Johnson and Johnson)
Source: Johnson and Johnson - August 20, 2018 Category: Pharmaceuticals Source Type: news
Ibalizumab Active in Multidrug Resistant HIV-1 Infection
THURSDAY, Aug. 16, 2018 -- Ibalizumab has antiviral activity among patients with multidrug resistant (MDR) HIV-1 infection, according to a study published in the Aug. 16 issue of the New England Journal of Medicine.
Brinda Emu, M.D., from the Yale... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 16, 2018 Category: Pharmaceuticals Source Type: news
Hospital superbugs developing ‘tolerance to alcohol disinfectants’
A multidrug-resistant bacterial species that can cause infections in hospitals is becoming increasingly tolerant to the alcohols used in handwash disinfectants, according to Australian researchers. (Source: Nursing Times)
Source: Nursing Times - August 2, 2018 Category: Nursing Source Type: news
Superbugs now also becoming resistant to alcohol disinfectants
Multidrug-resistant "superbugs" that can cause dangerous infections in hospitals are becoming increasingly resistant to alcohol-based hand sanitizers and disinfectants designed to hold them at bay, scientists said. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Hospital-associated bacterial species becoming tolerant to alcohol disinfectants
(American Association for the Advancement of Science) A multidrug-resistant bacterial species that can cause infections in hospitals is becoming increasingly tolerant to the alcohols used in handwash disinfectants, a new study finds. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 1, 2018 Category: Infectious Diseases Source Type: news
Multidrug-Resistant Infections: What's on the Horizon? Multidrug-Resistant Infections: What's on the Horizon?
As resistance develops to ' last-line ' antimicrobials, what ' s next in the treatment of serious bacterial infections?Society for Healthcare Epidemiology of America (SHEA) (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 18, 2018 Category: Consumer Health News Tags: Infectious Diseases Viewpoint Source Type: news
Zemdri (plazomicin) Approved by FDA for the Treatment of Adults with Complicated Urinary Tract Infections (cUTI)
SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multidrug resistant (MDR) gram-negative infections, today announced... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 25, 2018 Category: Drugs & Pharmacology Source Type: news
